{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T03:28:58Z","timestamp":1787801338278,"version":"build-2784847793"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201379"],"award-info":[{"award-number":["82201379"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82301724"],"award-info":[{"award-number":["82301724"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010227","name":"Nanjing Health Bureau Medical Science and Technology Development Foundation","doi-asserted-by":"publisher","award":["JQX24008"],"award-info":[{"award-number":["JQX24008"]}],"id":[{"id":"10.13039\/501100010227","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","award":["BK20220195"],"award-info":[{"award-number":["BK20220195"]}],"id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.neuropharm.2025.110317","type":"journal-article","created":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T18:54:17Z","timestamp":1738090457000},"page":"110317","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Effect of two novel GABAA receptor positive allosteric modulators on neuropathic and inflammatory pain in mice"],"prefix":"10.1016","volume":"269","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8241-1679","authenticated-orcid":false,"given":"Chu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Hong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"family":"Chun-Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian-Jun","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6015-5125","authenticated-orcid":false,"given":"Jun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"53","key":"10.1016\/j.neuropharm.2025.110317_bib1","doi-asserted-by":"crossref","first-page":"41795","DOI":"10.1074\/jbc.M110.149229","article-title":"Protein kinase C phosphorylation regulates membrane insertion of GABAA receptor subtypes that mediate tonic inhibition","volume":"285","author":"Abramian","year":"2010","journal-title":"J. Biol. Chem."},{"issue":"19","key":"10.1016\/j.neuropharm.2025.110317_bib2","doi-asserted-by":"crossref","first-page":"7132","DOI":"10.1073\/pnas.1403285111","article-title":"Neurosteroids promote phosphorylation and membrane insertion of extrasynaptic GABAA receptors","volume":"111","author":"Abramian","year":"2014","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2025.110317_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neuropharm.2014.09.021","article-title":"Modulation of neurosteroid potentiation by protein kinases at synaptic- and extrasynaptic-type GABAA receptors","volume":"88","author":"Adams","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2025.110317_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108333","article-title":"Preclinical characterization of zuranolone (SAGE-217), a selective neuroactive steroid GABA(A) receptor positive allosteric modulator","volume":"181","author":"Althaus","year":"2020","journal-title":"Neuropharmacology"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110317_bib5","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1093\/brain\/awae126","article-title":"Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice","volume":"147","author":"Barbour","year":"2024","journal-title":"Brain"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib6","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.cell.2009.09.028","article-title":"Cellular and molecular mechanisms of pain","volume":"139","author":"Basbaum","year":"2009","journal-title":"Cell"},{"issue":"41","key":"10.1016\/j.neuropharm.2025.110317_bib7","doi-asserted-by":"crossref","first-page":"12757","DOI":"10.1523\/JNEUROSCI.3340-09.2009","article-title":"Extrasynaptic GABAA receptors: form, pharmacology, and function","volume":"29","author":"Belelli","year":"2009","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110317_bib8","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuron.2011.12.012","article-title":"Extrasynaptic GABA(A) receptors: their function in the CNS and implications for disease","volume":"73","author":"Brickley","year":"2012","journal-title":"Neuron"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110317_bib9","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1113\/jphysiol.2014.280263","article-title":"Developmentally regulated neurosteroid synthesis enhances GABAergic neurotransmission in mouse thalamocortical neurones","volume":"593","author":"Brown","year":"2015","journal-title":"J. Physiol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110317_bib10","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/S0022-3565(24)36511-5","article-title":"Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3alpha-hydroxy-3beta-methyl-5alpha-pregnan-20-one), a selective, high-affinity, steroid modulator of the gamma-aminobutyric acid(A) receptor","volume":"280","author":"Carter","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110317_bib11","doi-asserted-by":"crossref","first-page":"5331","DOI":"10.1038\/ncomms6331","article-title":"Presynaptic GABAergic inhibition regulated by BDNF contributes to neuropathic pain induction","volume":"5","author":"Chen","year":"2014","journal-title":"Nat. Commun."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110317_bib12","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1124\/jpet.105.092320","article-title":"An inverse agonist selective for alpha5 subunit-containing GABAA receptors enhances cognition","volume":"316","author":"Dawson","year":"2006","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110317_bib13","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1124\/jpet.103.064360","article-title":"Structural determinants of the pharmacological properties of the GABAA receptor alpha6 subunit","volume":"309","author":"Drafts","year":"2004","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2025.110317_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.nbd.2020.105041","article-title":"The cornucopia of central disinhibition pain - an evaluation of past and novel concepts","volume":"145","author":"Forstenpointner","year":"2020","journal-title":"Neurobiol. Dis."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib15","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0022-3565(24)36837-5","article-title":"Anticonvulsant and behavioral effects of neuroactive steroids alone and in conjunction with diazepam","volume":"282","author":"Gasior","year":"1997","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110317_bib16","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s43141-021-00224-0","article-title":"GABA(A) receptors: structure, function, pharmacology, and related disorders","volume":"19","author":"Ghit","year":"2021","journal-title":"J. Genet. Eng. Biotechnol."},{"key":"10.1016\/j.neuropharm.2025.110317_bib17","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.phrs.2015.12.030","article-title":"Activation-induced regulation of GABAA receptors: is there a link with the molecular basis of benzodiazepine tolerance?","volume":"109","author":"Gravielle","year":"2016","journal-title":"Pharmacol. Res."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110317_bib18","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1212\/WNL.52.9.1917-a","article-title":"Progesterone therapy in women with epilepsy: a 3-year follow-up","volume":"52","author":"Herzog","year":"1999","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110317_bib19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pharmthera.2007.03.011","article-title":"Neurosteroid binding sites on GABA(A) receptors","volume":"116","author":"Hosie","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib20","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/ALN.0000000000002130","article-title":"Neuroinflammation and central sensitization in chronic and widespread pain","volume":"129","author":"Ji","year":"2018","journal-title":"Anesthesiology"},{"key":"10.1016\/j.neuropharm.2025.110317_bib21","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.ejphar.2015.03.056","article-title":"(+)-Borneol alleviates mechanical hyperalgesia in models of chronic inflammatory and neuropathic pain in mice","volume":"757","author":"Jiang","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110317_bib22","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/S0140-6736(17)31264-3","article-title":"Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial","volume":"390","author":"Kanes","year":"2017","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110317_bib23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.tibs.2021.01.011","article-title":"Direct structural insights into GABA(A) receptor pharmacology","volume":"46","author":"Kim","year":"2021","journal-title":"Trends Biochem. Sci."},{"issue":"7176","key":"10.1016\/j.neuropharm.2025.110317_bib24","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1038\/nature06493","article-title":"Reversal of pathological pain through specific spinal GABAA receptor subtypes","volume":"451","author":"Knabl","year":"2008","journal-title":"Nature"},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib25","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/S0022-3565(24)37827-9","article-title":"Lack of anticonvulsant tolerance to the neuroactive steroid pregnanolone in mice","volume":"287","author":"Kokate","year":"1998","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110317_bib26","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1007\/s13311-020-00883-w","article-title":"Prolonged use of NMDAR antagonist develops analgesic tolerance in neuropathic pain via nitric oxide reduction-induced GABAergic disinhibition","volume":"17","author":"Li","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"12","key":"10.1016\/j.neuropharm.2025.110317_bib27","doi-asserted-by":"crossref","first-page":"5970","DOI":"10.7150\/thno.58364","article-title":"A pain killer without analgesic tolerance designed by co-targeting PSD-95-nNOS interaction and alpha2-containning GABAARs","volume":"11","author":"Li","year":"2021","journal-title":"Theranostics"},{"key":"10.1016\/j.neuropharm.2025.110317_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2022.136545","article-title":"Intrathecally administered pizotifen alleviates neuropathic and inflammatory pain in mice by enhancing GABAergic inhibition","volume":"775","author":"Li","year":"2022","journal-title":"Neurosci. Lett."},{"issue":"Pt A","key":"10.1016\/j.neuropharm.2025.110317_bib29","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.neuropharm.2016.10.010","article-title":"Endogenous and synthetic neuroactive steroids evoke sustained increases in the efficacy of GABAergic inhibition via a protein kinase C-dependent mechanism","volume":"113","author":"Modgil","year":"2017","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110317_bib30","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1210\/en.2012-1772","article-title":"Characterization, neurosteroid binding and brain distribution of human membrane progesterone receptors delta and epsilon (mPRdelta and mPRepsilon) and mPRdelta involvement in neurosteroid inhibition of apoptosis","volume":"154","author":"Pang","year":"2013","journal-title":"Endocrinology"},{"issue":"32","key":"10.1016\/j.neuropharm.2025.110317_bib31","doi-asserted-by":"crossref","first-page":"12220","DOI":"10.1074\/jbc.RA119.008875","article-title":"Metabotropic, but not allosteric, effects of neurosteroids on GABAergic inhibition depend on the phosphorylation of GABA(A) receptors","volume":"294","author":"Parakala","year":"2019","journal-title":"J. Biol. Chem."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110317_bib32","doi-asserted-by":"crossref","first-page":"2311","DOI":"10.1096\/fasebj.6.6.1347506","article-title":"Neuroactive steroids","volume":"6","author":"Paul","year":"1992","journal-title":"Faseb. J."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110317_bib33","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1111\/j.1360-0443.1994.tb03743.x","article-title":"The benzodiazepine withdrawal syndrome","volume":"89","author":"Petursson","year":"1994","journal-title":"Addiction"},{"key":"10.1016\/j.neuropharm.2025.110317_bib34","doi-asserted-by":"crossref","first-page":"6803","DOI":"10.1038\/ncomms7803","article-title":"Analgesia and unwanted benzodiazepine effects in point-mutated mice expressing only one benzodiazepine-sensitive GABAA receptor subtype","volume":"6","author":"Ralvenius","year":"2015","journal-title":"Nat. Commun."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110317_bib35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.eplepsyres.2004.09.003","article-title":"Role of neurosteroids in catamenial epilepsy","volume":"62","author":"Reddy","year":"2004","journal-title":"Epilepsy Res."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/jne.13028","article-title":"Neurosteroid replacement therapy for catamenial epilepsy, postpartum depression and neuroendocrine disorders in women","volume":"34","author":"Reddy","year":"2022","journal-title":"J. Neuroendocrinol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1124\/jpet.123.001816","article-title":"Neurosteroids as novel anticonvulsants for refractory status epilepticus and medical countermeasures for nerve agents: a 15-year journey to bring ganaxolone from bench to clinic","volume":"388","author":"Reddy","year":"2024","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110317_bib38","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-3565(24)39026-3","article-title":"Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself","volume":"295","author":"Reddy","year":"2000","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"0 6","key":"10.1016\/j.neuropharm.2025.110317_bib39","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/epi.12289","article-title":"Neuroactive steroids for the treatment of status epilepticus","volume":"54","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"issue":"6755","key":"10.1016\/j.neuropharm.2025.110317_bib40","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1038\/44579","article-title":"Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes","volume":"401","author":"Rudolph","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2025.110317_bib41","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1146\/annurev.pharmtox.44.101802.121429","article-title":"Analysis of GABAA receptor function and dissection of the pharmacology of benzodiazepines and general anesthetics through mouse genetics","volume":"44","author":"Rudolph","year":"2004","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110317_bib42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1124\/jpet.118.252155","article-title":"Intravenously administered ganaxolone blocks diazepam-resistant lithium-pilocarpine-induced status epilepticus in rats: comparison with allopregnanolone","volume":"368","author":"Saporito","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110317_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1038\/sj.npp.1301403","article-title":"Are GABAA receptors containing alpha5 subunits contributing to the sedative properties of benzodiazepine site agonists?","volume":"33","author":"Savic","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"7904","key":"10.1016\/j.neuropharm.2025.110317_bib44","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/s41586-022-04517-3","article-title":"Differential assembly diversifies GABA(A) receptor structures and signalling","volume":"604","author":"Sente","year":"2022","journal-title":"Nature"},{"issue":"22","key":"10.1016\/j.neuropharm.2025.110317_bib45","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abg3362","article-title":"Molecular mechanisms of metabotropic GABA(B) receptor function","volume":"7","author":"Shaye","year":"2021","journal-title":"Sci. Adv."},{"issue":"8","key":"10.1016\/j.neuropharm.2025.110317_bib46","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2174\/1568026023393507","article-title":"Subunit composition, distribution and function of GABA(A) receptor subtypes","volume":"2","author":"Sieghart","year":"2002","journal-title":"Curr. Top. Med. Chem."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110317_bib47","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.tips.2018.03.006","article-title":"The benzodiazepine binding sites of GABA(A) receptors","volume":"39","author":"Sigel","year":"2018","journal-title":"Trends Pharmacol. Sci."},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110317_bib48","doi-asserted-by":"crossref","first-page":"7224","DOI":"10.1073\/pnas.1017719108","article-title":"Tonic inhibition of chronic pain by neuropeptide Y","volume":"108","author":"Solway","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110317_bib49","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.bja.2020.01.013","article-title":"Neuroactive steroids alphaxalone and CDNC24 are effective hypnotics and potentiators of GABA(A) currents, but are not neurotoxic to the developing rat brain","volume":"124","author":"Tesic","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"10.1016\/j.neuropharm.2025.110317_bib50","doi-asserted-by":"crossref","first-page":"817996","DOI":"10.3389\/fnmol.2022.817996","article-title":"Preventing phosphorylation of the GABA (A) R beta3 subunit compromises the behavioral effects of neuroactive steroids","volume":"15","author":"Vien","year":"2022","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110317_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173321","article-title":"The imidazodiazepine, KRM-II-81: an example of a newly emerging generation of GABAkines for neurological and psychiatric disorders","volume":"213","author":"Witkin","year":"2022","journal-title":"Pharmacol. Biochem. Behav."},{"issue":"35","key":"10.1016\/j.neuropharm.2025.110317_bib52","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202303113","article-title":"Ac4C enhances the translation efficiency of vegfa mRNA and mediates central sensitization in spinal dorsal horn in neuropathic pain","volume":"10","author":"Xu","year":"2023","journal-title":"Adv. Sci."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000231?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000231?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T04:23:42Z","timestamp":1777350222000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825000231"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":52,"alternative-id":["S0028390825000231"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110317","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of two novel GABAA receptor positive allosteric modulators on neuropathic and inflammatory pain in mice","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110317","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110317"}}